« Previous image
FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
Phase 2 clinical study for patients with diffuse cutaneous systemic sclerosis (dcSSc) or patients with pulmonary arterial hypertension (PAH)
SCLERODERMA WILL NOT TAKE MY SMILE – World Scleroderma Day 2017
Scleroderma app – now available for download
Press Release – Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
5th Systemic Sclerosis World Congress, Bordeaux. February 15-17 2018
World Scleroderma Day 2017
The first international EU-funded research project to decipher the optimal management on Systemic Sclerosis World Scleroderma Foundation
Read our latest newsletter
